Therefore, a complete blockage of the VEGF-signaling pathway by combining a ligand inhibitor, such as bevacizumab, with a multi-targeted kinase inhibitor, blocking the VEGF system on the receptor level (sorafenib) and also targeting compensatory pro-angiogenic mechanisms, could cause a synergistic inhibition of tumor angiogenesis. The gene discussed is VEGFA; the disease is neoplasm.